RGBPP Stock, Regen BioPharma Information

Regen is focused on identifying undervalued regenerative medicine applications in the stem cell/immunotherapy space and rapidly advancing these technologies through pre clinical and Phase I/II clinical trials. Currently the Company is developing products treating blood disorders using small molecules and gene silencing DiffronC , treating cancer with immunotherapy dCellVax , modulating key molecular processes in cancer stem cell through its patented molecular targeting approaches BORIS , and repairing damaged bone marrow in patients with aplastic anemia and chemotherapy/radiotherapy treated cancer patients HemaXellerate .